11400 Tomahawk Creek Pkwy, Suite 340, Leawood, KS 66211
Phone: 1-(844) 272-8262 Fax: (913) 904-9641
www.aratana.com
August 14, 2017
Via EDGAR Transmission
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
|
|
|
| Re: | Aratana Therapeutics, Inc. |
|
| Registration Statement on Form S-3 |
|
| Filed August 4, 2017 |
|
| Registration No. 333-219681 |
Dear Mr. Edwards:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on August 16, 2017, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Aratana Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff of the Securities and Exchange Commission. Please contact Peter Handrinos of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Nicole McNeil at (617) 880-4579, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
|
|
|
| Sincerely yours, | |
|
|
|
| Aratana Therapeutics, Inc. | |
|
|
|
| By: | /s/ Steven St. Peter |
|
| Steven St. Peter, M.D. |
|
| President and Chief Executive Officer |
|
|
cc: | John C. Ayres, General Counsel, Aratana Therapeutics, Inc. |
| Peter N. Handrinos, Esq., Latham & Watkins LLP |
| Nicole McNeil, Esq., Latham & Watkins LLP |